New arrhythmia drug provides only modest efficacy and no clear safety benefits say researchers
Monday, April 5, 2010 - 17:21
in Health & Medicine
In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.